Drug · CHEMBL3301587

DURVALUMAB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. DURVALUMAB. Drugs and targets, record CHEMBL3301587. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL3301587

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: DURVALUMAB; ChEMBL
ChEMBL ID: CHEMBL3301587; ChEMBL
Type: Antibody; ChEMBL
Brand names: Imfinzi; ChEMBL
Other names: MEDI-4736, MEDI4736; ChEMBL
Open Targets' highest stage: Approval, for 5 of its 139 diseases, from ATC, ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
CD274	Programmed cell death 1 ligand 1	Programmed cell death 1 ligand 1 inhibitor	INHIBITOR	https://conductscience.org/library/genes/29126

Source ChEMBL

Diseases139

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
non-small cell lung carcinoma	Approval	EMA Human Drugs, FDA and PMDA	182	179	https://conductscience.org/library/drugs?q=MONDO_0005233
hepatocellular carcinoma	Approval	ClinicalTrials.gov	73	72	https://conductscience.org/library/drugs?q=MONDO_0007256
small cell lung carcinoma	Approval	DailyMed	72	71	https://conductscience.org/library/drugs?q=MONDO_0008433
head and neck squamous cell carcinoma	Phase 3	ClinicalTrials.gov	37	37	https://conductscience.org/library/drugs?q=MONDO_0010150
breast cancer	Phase 3	ClinicalTrials.gov	34	34	https://conductscience.org/library/drugs?q=MONDO_0007254
biliary tract cancer	Phase 3	ClinicalTrials.gov	31	30	https://conductscience.org/library/drugs?q=MONDO_0003060
colorectal cancer	Phase 2	ClinicalTrials.gov	27	27	https://conductscience.org/library/drugs?q=MONDO_0005575
ovarian cancer	Phase 3	ClinicalTrials.gov	25	25	https://conductscience.org/library/drugs?q=MONDO_0008170
triple-negative breast carcinoma	Phase 3	ClinicalTrials.gov	20	20	https://conductscience.org/library/drugs?q=MONDO_0005494
cancer	Phase 3	ClinicalTrials.gov	15	15	https://conductscience.org/library/drugs?q=MONDO_0004992

1 to 10 of 139Source Open Targets

See all 139 diseases

Trials788

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT03298451	Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma	Phase 3	1,324	2023-06-18	durvalumab	Its name	ClinicalTrials.gov
NCT03164616	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).	Phase 3	1,186	2022-04-07	durvalumab	Its name	ClinicalTrials.gov
NCT02516241	Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	Phase 3	1,126	2021-05-13	durvalumab	Its name	ClinicalTrials.gov
NCT02453282	Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)	Phase 3	1,118	2019-11-29	durvalumab	Its name	ClinicalTrials.gov
NCT03732677	Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC	Phase 3	1,063	2025-07-03	durvalumab	Its name	ClinicalTrials.gov
NCT01693562	A Phase 1/2 Study to Evaluate MEDI4736	Phase 1/2	1,022	2021-05-13	durvalumab	Its name	ClinicalTrials.gov
NCT03043872	Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)	Phase 3	987	2021-03-04	durvalumab	Its name	ClinicalTrials.gov
NCT02542293	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)	Phase 3	953	2022-05-24	durvalumab	Its name	ClinicalTrials.gov
NCT03084471	An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.	Phase 3	867	2021-06-15	durvalumab	Its name	ClinicalTrials.gov
NCT02551159	Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer	Phase 3	823	2021-10-13	MEDI4736	Its name	ClinicalTrials.gov

1 to 10 of 788

See all 788 trials

Comparisons in its trials104

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: Proportion of Patients Who Undergo Cystectomy	469 of 533	441 of 530	1,063	NCT03732677	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: Pathologic Complete Response (pCR) Rates at Time of Cystectomy	199 of 533	146 of 530	1,063	NCT03732677	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause	27 of 533	29 of 526	1,059	NCT03732677	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: serious adverse events	326 of 530	287 of 526	1,056	NCT03732677	Trial comparisons
Durva + SoC CCRT vs Placebo + SoC CCRT: deaths from any cause	91 of 385	112 of 385	770	NCT03830866	Trial comparisons
Durva + SoC CCRT vs Placebo + SoC CCRT: serious adverse events	113 of 385	90 of 384	769	NCT03830866	Trial comparisons
Durvalumab (MEDI4736) vs Placebo: deaths from any cause	262 of 475	154 of 234	709	NCT02125461	Trial comparisons
Durvalumab (MEDI4736) vs Placebo: serious adverse events	138 of 475	54 of 234	709	NCT02125461	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin: deaths from any cause	308 of 341	326 of 344	685	NCT03875235	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin: serious adverse events	168 of 338	152 of 342	680	NCT03875235	Trial comparisons

1 to 10 of 104

See all 104 comparisons in its trials

Papers from its trials411

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42225005	RESULT	1	PubMed
40091844	RESULT	1	PubMed
40069402	RESULT	1	PubMed
39737219	RESULT	1	PubMed
39513948	RESULT	1	PubMed
38319896	RESULT	2	PubMed
37196069	RESULT	1	PubMed
37075781	RESULT	1	PubMed
36809050	RESULT	1	PubMed
36600534	RESULT	1	PubMed

1 to 10 of 411

See all 411 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL3301587

GET https://conductscience.org/api/drugs/v1/CHEMBL3301587/diseases?page=2

API reference For AI assistants